Nicholette Zeliadt manages The Transmitters’s staff reporters and interns, and she commissions and edits news articles. She joined The Transmitter as news writer in 2014. Before that, she was a freelance writer and editor. Her work has appeared in The New York Times, Scientific American, Nature Medicine, Science and The Scientist.
Nicholette Zeliadt
Managing editor
The Transmitter
From this contributor
Leaving lasting marks with Tessa Montague
By
Nicholette Zeliadt
9 February 2024 | 7 min read
Spotted around the web: INSAR; cerebellar gene expression; pangenome
By
Jill Adams, Giorgia Guglielmi, Nicholette Zeliadt, Kristin Ozelli
12 May 2023 | 4 min read
Spotted around the web: Mapping histones; COVID-19 births; acetaminophen lawsuits
By
Jill Adams, Katharine Gammon, Peter Hess, Nicholette Zeliadt
4 November 2022 | 3 min read
New diagnostic code for PTEN syndrome may spur research
By
Nicholette Zeliadt
3 October 2022 | 4 min read
Education
- Ph.D. in environmental health, University of Minnesota
- B.A. in biochemistry, University of Iowa
Fellowships
- AAAS Mass Media Fellowship
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read